Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP203797.RA9oaz6-FbAAqzJyK7MFCwfawAi04J1i7swLdp4BKA-rE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP203797.RA9oaz6-FbAAqzJyK7MFCwfawAi04J1i7swLdp4BKA-rE130_assertion type Assertion NP203797.RA9oaz6-FbAAqzJyK7MFCwfawAi04J1i7swLdp4BKA-rE130_head.
- NP203797.RA9oaz6-FbAAqzJyK7MFCwfawAi04J1i7swLdp4BKA-rE130_assertion description "[We identified TET2 deletions in 50/893 patients (26 males, 24 females; 44-87 years) resulting in a 5.6% frequency [22/425 AML (5.2%), 15/217 chronic myelomonocytic leukaemia (CMML; 6.9%), 9/188 myelodysplastic syndromes (4.8%), 4/63 myeloproliferative neoplasms (6.3%)].]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP203797.RA9oaz6-FbAAqzJyK7MFCwfawAi04J1i7swLdp4BKA-rE130_provenance.
- NP203797.RA9oaz6-FbAAqzJyK7MFCwfawAi04J1i7swLdp4BKA-rE130_assertion evidence source_evidence_literature NP203797.RA9oaz6-FbAAqzJyK7MFCwfawAi04J1i7swLdp4BKA-rE130_provenance.
- NP203797.RA9oaz6-FbAAqzJyK7MFCwfawAi04J1i7swLdp4BKA-rE130_assertion SIO_000772 22017486 NP203797.RA9oaz6-FbAAqzJyK7MFCwfawAi04J1i7swLdp4BKA-rE130_provenance.
- NP203797.RA9oaz6-FbAAqzJyK7MFCwfawAi04J1i7swLdp4BKA-rE130_assertion wasDerivedFrom befree-20140225 NP203797.RA9oaz6-FbAAqzJyK7MFCwfawAi04J1i7swLdp4BKA-rE130_provenance.
- NP203797.RA9oaz6-FbAAqzJyK7MFCwfawAi04J1i7swLdp4BKA-rE130_assertion wasGeneratedBy ECO_0000203 NP203797.RA9oaz6-FbAAqzJyK7MFCwfawAi04J1i7swLdp4BKA-rE130_provenance.